Effectiveness bank home page. Opens new window Subject search results

You have found 32 entries. Starting with the most recently added or updated entries, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.

Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the main topic addressed or by the most recently published documents


If you have not found what you want you could:
Tab back to the Subject search page/tab to amend your original search.
Try a new search (clears your previous selection).
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo Drug and Alcohol Findings logo



STUDY 2017 HTM file
Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: A randomized clinical noninferiority trial

Can monthly injections of extended-release naltrexone be considered on a par with the standard daily opioid substitute in Norway for people wanting to maintain abstinence from heroin?

REVIEW 2017 HTM file
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate

In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification, extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none was there high quality evidence.

REVIEW 2011 HTM file
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence

This impressive assessment of what evaluation research means for alcohol dependence treatment in Britain is distinguished by reviews of the latest literature on the sub-topics it covers; in some cases these starkly reveal the inadequacies of the evidence base.

MATRIX CELL 2016 HTM file
Alcohol Matrix cell C3: Management/supervision; Medical treatment

Seminal and key studies on the impact of management in medical interventions and treatment in medical settings. Asks how we can identify effective clinicians and effective medications, and highlights the remarkable transformation brought about in the 1950s at a Massachusetts clinic.

MATRIX CELL 2016 HTM file
Alcohol Matrix cell B3: Practitioners; Medical treatment

The most important seminal and key studies and reviews shedding light on the impact of the practitioner in medical interventions and treatment for alcohol problems in medical settings.

MATRIX CELL 2016 HTM file
Alcohol Matrix cell A3: Interventions; Medical treatment

Seminal and key studies and reviews on the effectiveness of medical interventions and treatment in medical settings.

REVIEW 2013 HTM file
Metaanalysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Naltrexone and acamprosate both modestly curtail drinking among alcohol-dependent patients, but which is best in which circumstances and for which treatment goals? To find out this review compared the medications’ performance when separately benchmarked against a placebo, bringing to bear much more data than is available from the few trials which directly compared the two drugs.

REVIEW 2015 HTM file
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis

Whether differences between the patients mean impacts of the alcohol treatment medications acamprosate and naltrexone vary between Europe and the USA was the issue which motivated this fresh analysis of randomised trials. It confirmed the medications’ efficacy and found no evidence that this differed in European trials versus those conducted elsewhere.

REVIEW 2011 HTM file
The efficacy of disulfiram for the treatment of alcohol use disorder

Given effective supervision from family or clinicians to help ensure patients keep taking the tablets, this first systematic synthesis of research finds that on average the drug disulfiram, which produces an unpleasant physical reaction to drinking, does act as an aid to abstinence in the treatment of alcohol dependence.

HOT TOPIC 2016 HTM file
Prizes for not using drugs?

‘Hot topics’ offer background and analysis on important issues which sometimes generate heated debate. Contingency management programmes reward patients for complying with treatment or not engaging in undesired substance use. It works, but often only temporarily – and perhaps at the cost of eroding the patient’s confidence and motivation.


Select search results page

NEXT 1 2 3 4